Mankind Pharma Limited — Important, 22-11-2024: General Updates

Mankind Pharma has received an order from the Additional Commissioner of CGST, Meerut, imposing a penalty of INR 2.91 crore related to the financial years 2017-18 to 2021-22, citing the claim of inadmissible Input Tax Credit. The company contests the order, stating it is arbitrary and unjustified, given that the relevant tax was already paid along with interest in January 2022. Mankind Pharma plans to appeal the order, believing the case should not fall under Section 74 of the CGST Act. Importantly, the company assess that this situation will not materially impact its financials, operations, or overall activities. Investors should monitor this case closely, as outcomes could affect future compliance and operational dynamics.